Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy

Literals

fabio:hasPublicationYear
- 2025
ou:bibtex
- @article{Agundez2025,title = {Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy},journal = {Clinical Pharmacology and Therapeutics},year = {2025},author = {Eadon, M.T. and Hein, D.W. and Andersen, M.A. and Chapman, A.B. and Cooper-DeHoff, R.M. and Desta, Z. and Duarte, J.D. and Elchynski, A.L. and Gaedigk, A. and Karol, S.E. and Limdi, N.A. and Lteif, C. and Sosinski, L. and Zubiaur, P. and Whirl-Carrillo, M. and Klein, T.E. and Caudle, K.E. and Donnelly, R.S. and Ag{\'u}ndez, J.A.G.}}
ou:urlOrcid
- http://www.scopus.com/inward/record.url?eid=2-s2.0-105016631276&partnerID=MN8TOARS
bibo:issn
- 0009-9236
dcterms:creator
- Eadon M.T.
ou:eid
- 2-s2.0-105016631276
vivo:identifier
- 2025-7026
bibo:doi
- 10.1002/cpt.70071
dcterms:contributor
- Eadon M.T. et al.
bibo:eissn
- 1532-6535
dcterms:publisher
- Clinical Pharmacology and Therapeutics
ou:tipoPublicacion
- Article
dcterms:title
- Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy
vcard:url
- https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105016631276&origin=inward
ou:urlScopus
- https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105016631276&origin=inward
bibo:volume
- 118